The EasySep™ Mouse Biotin Positive Selection Kit II is designed to isolate cells that are labeled with biotinylated antibodies. Desired cells are targeted with antibody complexes recognizing biotin and dextran-coated magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Cells of interest remain in the tube while unwanted cells are poured off.
This product replaces the EasySep™ Mouse Biotin Positive Selection Kit (Catalog #18556).
Cell Type B Cells, Dendritic Cells, Granulocytes and Subsets, Hematopoietic Stem and Progenitor Cells, Macrophages, Marrow Stromal Cells, Mesenchymal Stem and Progenitor Cells, Monocytes, Mononuclear Cells, Myeloid Cells, NK Cells, Other, Plasma, T Cells
Species Mouse
Sample Source Bone Marrow, Other, Spleen
Selection Method Positive
Application Cell Isolation
Brand EasySep, RoboSep
Area of Interest Immunology
Data Figures
Starting with mouse splenocytes, the purities of the start and final isolated fractions in the above example are 20.5% and 97.5%, respectively, using a biotinylated anti-mouse CD4 antibody and EasySep™ Mouse Biotin Positive Selection Kit II (as assessed using PE-conjugated streptavidin).
Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. A. Dangi et al. Journal of the American Society of Nephrology : JASN 2022 oct
Abstract
BACKGROUND In kidney transplantation, early allograft inflammation impairs long-term allograft function. However, precise mediators of early kidney allograft inflammation are unclear, making it challenging to design therapeutic interventions. METHODS We used an allogeneic murine kidney transplant model in which CD45.2 BALB/c kidneys were transplanted to CD45.1 C57BL/6 recipients. RESULTS Donor kidney resident macrophages within the allograft expanded rapidly in the first 3 days. During this period, they were also induced to express a high level of Ccl8, which, in turn, promoted recipient monocyte graft infiltration, their differentiation to resident macrophages, and subsequent expression of Ccl8. Enhanced graft infiltration of recipient CCR8+ T cells followed, including CD4, CD8, and ?? T cells. Consequently, blocking CCL8-CCR8 or depleting donor kidney resident macrophages significantly inhibits early allograft immune cell infiltration and promotes superior short-term allograft function. CONCLUSIONS Targeting the CCL8-CCR8 axis is a promising measure to reduce early kidney allograft inflammation.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Legal Statement: Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
